Viral hepatitis elimination: Towards a hepatitis-free world

Maria Buti; Antonio Craxi; Graham R Foster; Mojca Maticic; Francesco Negro; Stefan Zeuzem; Fabien Zoulim

doi:10.1016/j.jhep.2022.06.034

Viral hepatitis elimination: Towards a hepatitis-free world

J Hepatol. 2022 Nov;77(5):1444-1447. doi: 10.1016/j.jhep.2022.06.034. Epub 2022 Jul 27.

Authors

Maria Buti¹, Antonio Craxi², Graham R Foster³, Mojca Maticic⁴, Francesco Negro⁵, Stefan Zeuzem⁶, Fabien Zoulim⁷

Affiliations

¹ Liver Unit, Hospital Universitario Valle Hebron and Civerehd del Instituto Carlos III, Barcelona, Spain.
² PROMISE, University of Palermo, Italy.
³ Barts Liver Centre, The Blizard Institute, QMUL, London UK. Electronic address: g.r.foster@qmul.ac.uk.
⁴ Clinic for Infectious Diseases, University Medical Centre Ljubljana and Medical Faculty, University of Ljubljana, Slovenia.
⁵ Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1211 Geneva 14, Switzerland.
⁶ Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
⁷ INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, Lyon, France.

PMID: 35907517
DOI: 10.1016/j.jhep.2022.06.034

Abstract

Advances in diagnostics and therapeutics have brought the elimination of chronic viral hepatitis into focus. The World Health Organization has defined the targets for elimination, but it is unclear how these can be achieved and how they should be measured. The goal of this special conference was to examine current efforts and metrics to assess progress towards elimination.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use
Disease Eradication
Hepatitis A*
Hepatitis, Viral, Human* / diagnosis
Hepatitis, Viral, Human* / epidemiology
Hepatitis, Viral, Human* / prevention & control
Humans
World Health Organization

Substances

Antiviral Agents